# Advanced Biodesign

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/advanced-biodesign

- Industry: Pharmaceuticals
- Headquarters: France
- Website: www.a-biodesign.com
- Total disclosed funding: $26M
- Latest round: Series D (Mar 1, 2023)
- Investors on record: 1

## About

Advanced Biodesign focuses on developing innovative therapies to combat drug resistance in cancer treatments, particularly targeting patients with high ALDH1 levels through its unique product offerings.Advanced Biodesign is dedicated to the research and development of advanced cancer therapies. The company is headquartered in France and has been actively involved in the oncology space since its inception. The founder of the company has a notable history in biotechnology, although specific details of previous enterprises are not disclosed. As of January 2024, Advanced Biodesign completed a Series D funding round, raising EUR 2.71 million, bringing the total amount raised to EUR 2.71 million, with a current company valuation of EUR 55.44 million.Advanced BioDesign specializes in the development of innovative therapies aimed at overcoming drug resistance in cancer treatment, particularly for patients with elevated levels of ALDH1. The lead product, ABD-3001, is a small-molecule inhibitor targeting the ALDH family of enzymes, currently in the initial stages of clinical development and being evaluated for efficacy across various malignancies, including acute myeloid leukemia, non-small cell lung cancer, and melanoma. The primary end users of these treatments are oncology patients facing challenges regarding chemotherapy resistance, with products primarily aimed at markets across Europe and North America.In the most recent year, Advanced Biodesign reported revenue of EUR 44,940.20, while its EBITDA for the same year was EUR -3,247,586.20. The company's revenue model is centered around strategic partnerships and collaborations with healthcare providers and research institutions involved in oncology, which may include milestone payments associated with clinical trial successes and regulatory approvals, as well as potential royalties from product sales.Advanced Biodesign plans to leverage the recent Series D funding of EUR 2.71 million to support the clinical development of its lead product, ABD-3001, and potentially expand its offerings. The company aims to introduce new products in the oncology sector and intends to expand its market reach into additional territories within Europe and North America by 2025, focusing on enhancing access to its innovative therapies.

## Funding rounds

- Series D, Mar 1, 2023, $1.9M — Xerys Gestion
- Series D, Sep 2, 2021, $7.7M — Xerys Gestion
- Series D, Mar 20, 2020, $8.3M — Xerys Gestion
- Series D, Jul 18, 2018, $2.4M — Xerys Gestion
- Series D, Dec 27, 2017, $0.7M — Xerys Gestion
- Series D, Jan 18, 2017, $1.9M — Xerys Gestion
- Series B, Jul 22, 2016, $0.1M — Xerys Gestion
- Series B, Mar 31, 2016, $1M — Xerys Gestion
- Series B, Apr 16, 2015, $0.8M — Xerys Gestion
- Series B, Aug 5, 2014, $0.9M — Xerys Gestion
- Series B, Jan 28, 2014, $0.5M — Xerys Gestion

## Investors

- Xerys Gestion (https://capitalatlas.ai/funds/xerys-gestion) — Series B, Series D